USA flag logo/image

An Official Website of the United States Government

Low-Cost Digital Gene Expression System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44CA130275
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
INTELLIGENT BIO-SYSTEMS, INC.
34 Bear Hill Rd. Waltham, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Low-Cost Digital Gene Expression System
Agency: HHS
Contract: 2R44CA130275-02A1
Award Amount: $1,597,096.00
 

Abstract:

DESCRIPTION (provided by applicant): As the second most common cause of death in the US, cancer is caused by random mutations in an organism's genome. Although precise knowledge of the genomic sequence within neoplastic tissues can be an indicator for treatment, for example the erbB-2 receptor gene (Her-2) for breast cancer, such correlations are few and often do not adequately define tumor subtypes important in therapeutic decisions. Such inability to identify a subclass of tumors which may not respond tostandard therapies can restrict the development of more efficacious treatment strategies. The analysis of gene expression represents an indirect measure of the genetic alterations in tumors through the analysis of regulatory pathways. Microarray technologies have proven to be powerful tools and offer the promise of better clinical decision-making based on tumor phenotypes. Highly promising preliminary studies of leukemia, lymphomas, and solid neoplasms demonstrate that gene expression data can highlight differences between otherwise histologically identical diseases. However, microarray-based technologies are limited in their ability to analyze low expression levels. We use of a unique sequencing by synthesis technology as a digital gene expression system toobtain precise counts of expressed mRNA molecules. This can provide an order of magnitude more sensitivity than microarray systems. In this Phase II project, we will build upon the sample preparation protocols developed in Phase I and use these with an extremely low-cost, proprietary, next-generation sequencing system that can perform the sequencing required for a gene expression study for about 100 or about 1/20th the price of the most competitive sequencing method. PUBLIC HEALTH RELEVANCE: Ultimately, the ability to produce very inexpensive gene expression and detailed DNA sequence information related to cancer will lead for a much wider use of expression and sequence analyses for research and treatment of this devastating disease. In addition, the ability to analyze complex organisms' genomes at a very low cost will both lead to accelerated discoveries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individualgenotypes rather than just observed symptoms.

Principal Investigator:

Steven J. Gordon
781-466-8050
sgordon@intelligentbiosystems.com

Business Contact:

Steven Gordon
781-466-8050
sgordon@intelligentbiosystems.com
Small Business Information at Submission:

INTELLIGENT BIO-SYSTEMS, INC.
34 Bear Hill Rd. Waltham, MA -

EIN/Tax ID: 120190018
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No